Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -4.01% and Operating profit at -22.53% over the last 5 years
2
Negative results in Sep 25
3
With ROE of 2.02%, it has a expensive valuation with a 2.80 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 9,907 Million (Mid Cap)
139.00
NA
0.24%
-0.01
2.59%
2.27
Revenue and Profits:
Net Sales:
698 Million
(Quarterly Results - Dec 2025)
Net Profit:
30 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.73%
0%
-2.73%
6 Months
-11.32%
0%
-11.32%
1 Year
-2.23%
0%
-2.23%
2 Years
-8.1%
0%
-8.1%
3 Years
-16.23%
0%
-16.23%
4 Years
-0.23%
0%
-0.23%
5 Years
-31.35%
0%
-31.35%
Yantai Dongcheng Biochemicals Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-4.01%
EBIT Growth (5y)
-22.53%
EBIT to Interest (avg)
8.10
Debt to EBITDA (avg)
1.13
Net Debt to Equity (avg)
0.05
Sales to Capital Employed (avg)
0.48
Tax Ratio
38.84%
Dividend Payout Ratio
35.89%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.52%
ROE (avg)
7.61%
Valuation key factors
Factor
Value
P/E Ratio
139
Industry P/E
Price to Book Value
2.80
EV to EBIT
73.79
EV to EBITDA
36.58
EV to Capital Employed
2.37
EV to Sales
4.99
PEG Ratio
NA
Dividend Yield
0.51%
ROCE (Latest)
3.21%
ROE (Latest)
2.02%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
698.00
659.40
5.85%
Operating Profit (PBDIT) excl Other Income
143.70
159.80
-10.08%
Interest
43.80
81.20
-46.06%
Exceptional Items
0.20
0.10
100.00%
Consolidate Net Profit
29.90
54.50
-45.14%
Operating Profit Margin (Excl OI)
125.00%
156.80%
-3.18%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 5.85% vs -5.37% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -45.14% vs 3.02% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,722.60
2,852.40
-4.55%
Operating Profit (PBDIT) excl Other Income
572.20
456.10
25.45%
Interest
138.90
98.20
41.45%
Exceptional Items
0.90
-84.70
101.06%
Consolidate Net Profit
154.40
141.40
9.19%
Operating Profit Margin (Excl OI)
129.40%
98.70%
3.07%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -4.55% vs -12.43% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 9.19% vs -44.37% in Dec 2024
About Yantai Dongcheng Biochemicals Co., Ltd. 
Yantai Dongcheng Biochemicals Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






